Core Insights - Olive Garden is piloting smaller, lower-priced meals to meet consumer demand for better value dining, which will be rolled out nationwide in January 2026 [1] - The rise in popularity of GLP-1 receptor agonists, such as Ozempic, is influencing dining habits, with users reportedly dining out less frequently but spending more when they do [2][3] - Many restaurants are adapting their menus to cater to the needs of GLP-1 users, with a focus on high-protein and high-fiber options [3][5] Group 1: Company Initiatives - Olive Garden's smaller portion meals include unlimited breadsticks and are designed to appeal to a broader customer base, not just GLP-1 users [1][4] - Chipotle has introduced a new high-protein chicken cup priced around $4, aligning with current consumer trends for budget-friendly and protein-rich options [1] - Smoothie King launched a GLP-1 exclusive menu featuring high-protein and fiber-rich smoothies, indicating a proactive approach to meet the dietary needs of this demographic [6] Group 2: Market Trends - Research indicates that households with GLP-1 users are spending more on dining out, contradicting initial concerns that these medications would reduce restaurant visits [2] - 59% of Americans prefer restaurants that offer flexible or customizable portion sizes, with this preference rising to 73% among GLP-1 users [5] - A significant portion of restaurant operators (43%) remain uninterested in catering to GLP-1 users, despite the growing trend and demand for tailored dining options [7]